PIRS - More on Pieris Pharmaceuticals Q3 earnings miss

Pieris Pharmaceuticals (PIRS) Q3 net loss was $14.3M or EPS of$0.26, misses consensus by $0.13. This compares to a net loss of $2.6M or EPS loss of $0.05.G&A expense were $4.1M, compared to $4.8M.R&D expenses were $11.8M, compared to $13.2M.Cash, cash equivalents, and investments totaled $82.6M for quarter ended September 30.Company raised $9.7M in net proceeds from investment fund Pontifax through its ATM equity facility."Within our respiratory franchise, we are pleased with AstraZeneca's commitment to the continued clinical development of PRS-060/AZD1402 and are happy to announce that preparations for a global phase 2a study of that program are complete. The study will be performed using a dry powder formulation in moderate asthmatics and will assess FEV1 improvement," said Stephen S. Yoder, President and CEO.Previously: Pieris Pharmaceuticals EPS misses by $0.13, misses on revenue (Nov. 4)

For further details see:

More on Pieris Pharmaceuticals Q3 earnings miss